Henry Schein
- Market cap
- 9.32B
- P/E (TTM)i
- 24.39
- P/Bi
- 2.95
- EPSi
- 3.27
- Div yieldi
- 0.00%
- 52W posi
- 72%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Fair Value how this is computed
- Implied fair-value range of 59.54-83.23, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is +17.2% above the average-multiple fair value of 71.38.
Valuation each multiple against its own 5-year range
Vs. peers Medical Distribution
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Henry Schein (HSIC) | 9.32B | 24.39 | 2.95 | 0.00% |
| McKesson (MCK) | 106.14B | 24.31 | -25.03 | 0.36% |
| Cencora (COR) | 60.54B | 23.55 | 19.84 | 0.74% |
| Cardinal Health (CAH) | 53.76B | 32.11 | -18.65 | 0.88% |
| Akso Health (AHG) | 1.04B | -40.33 | 5.73 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 1.6% above Morningstar's fair value estimate.
Fair value
Henry Schein Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% premium over our quantitative fair value estimate of $82.34 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating.
The firm's unfavorable dividend structure undermines our quantitative valuation. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. Reflecting the firm's dividends is its forward dividend yield of 0%, which falls in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are overvalued.
Alternatively, the firm's valuation metrics are reassuring. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.6, for example, lies in the top 30% compared with global peers. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-10-08 07:27:26 · For reference only, not investment advice and not tailored to your situation.